Market Overview:
The global ertapenem for injection market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of infectious diseases, rising demand for better and faster-acting antibiotics, and growing awareness about the benefits of ertapenem therapy. The global ertapenem for injection market is segmented on the basis of purity into >98% and >99%. The >99% purity segment is expected to grow at a higher CAGR than the >98% purity segment during the forecast period. This can be attributed to increasing demand for high-purity drugs due to their superior efficacy and safety profiles. On the basis of application, the global ertapenem for injection market is divided into intravenous injection and intramuscular injection.
Product Definition:
Ertapenem is a carbapenem antibiotic used to treat a wide variety of infections. It works by stopping the growth of bacteria.
Purity >98%:
Purity 98% is a new term in the industry and it has gained popularity because of its ability to deliver high quality products with few impurities. It is used for manufacturing drugs that are sold commercially as Ertapenem injection. The drug was developed by Cipla, an Indian based pharmaceutical company which also happens to be one of the largest generic drug manufacturers in the world.
Purity >99%:
Purity >99% is a special type of Isolite that has 99.5% purity and it's manufactured by the supercritical fluid CO2 method. It helps in increasing the strength of antibiotics as they are more resistant to heat, light, and oxidation. Thus, it increases their ability to fight against bacterial infections effectively.
Application Insights:
Based on the application, the global ertapenem for injection market is segmented into intravenous injection and intramuscular injection. The intravenous segment dominated the market in terms of revenue in 2017 owing to availability of various formulations such as 10% solution for slow infusion, 20% solution for rapid infusions and 30% powder-for-injection combination. Increasing awareness about hospital acquired infections has propelled demand for antibiotics resulting in growth of this segment during recent years.
The intramuscular segment is expected to grow at a lucrative rate over the forecast period due to increasing incidences of penicillin allergic reactions and adverse drug reactions (ADRs). ADRs are majorly seen with benzylpenicillin however other types also exhibit similar patterns especially when compared with intermediate duration penicillins such as amoxicillin/clavulanate potassium that are used commonly nowadays.
Regional Analysis:
North America dominated the global ertapenem for injection market in 2017. The rising number of drug-resistant infections, increasing healthcare expenditure, and growing awareness about antibiotic alternatives are some of the major factors responsible for its largest share. In addition, favorable reimbursement policies and a high adoption rate of advanced therapeutics are also contributing to its large share.
Asia Pacific is expected to be the fastest-growing regional market during the forecast period owing to various factors such as improving economic conditions in emerging countries such as India & China and increasing geriatric population base that require more attention due to their higher susceptibility towards infectious diseases. Moreover, rapidly developing healthcare infrastructure coupled with an increase in government spending on health sector will also boost growth over this region’s estimated period from 2018 to 2030 (see Figure 1).
Growth Factors:
- Increasing incidence of hospital-acquired infections (HAIs) and increasing demand for Ertapenem as a treatment option for HAIs.
- Rising geriatric population, who are more susceptible to hospital-acquired infections, is also expected to drive the growth of the Ertapenem market.
- Growing number of clinical studies supporting the use of Ertapenem in various indications is likely to boost its adoption rates in the coming years.
- Availability of generic versions of Ertapenem is expected to further fuel the growth prospects for this market during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Ertapenem for Injection Market Research Report
By Type
Purity >98%, Purity >99%
By Application
Intravenous Injection, Intramuscular Injection
By Companies
Savior Lifetec Corporation, ACS Dobfar, Zhejiang Hisun Pharmaceutical, Sun Pharma, Zhejiang Hisoar, Kaliberr Labs, Qilu Pharmaceutical
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
198
Number of Tables & Figures
139
Customization Available
Yes, the report can be customized as per your need.
Global Ertapenem for Injection Market Report Segments:
The global Ertapenem for Injection market is segmented on the basis of:
Types
Purity >98%, Purity >99%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Intravenous Injection, Intramuscular Injection
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Savior Lifetec Corporation
- ACS Dobfar
- Zhejiang Hisun Pharmaceutical
- Sun Pharma
- Zhejiang Hisoar
- Kaliberr Labs
- Qilu Pharmaceutical
Highlights of The Ertapenem for Injection Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity >98%
- Purity >99%
- By Application:
- Intravenous Injection
- Intramuscular Injection
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Ertapenem for Injection Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Ertapenem is a penicillin antibiotic that is used to treat infections caused by certain types of bacteria. It is usually given as an injection into a vein. Ertapenem can be effective against many types of bacteria, including some strains of staphylococcus and streptococcus.
Some of the major players in the ertapenem for injection market are Savior Lifetec Corporation, ACS Dobfar, Zhejiang Hisun Pharmaceutical, Sun Pharma, Zhejiang Hisoar, Kaliberr Labs, Qilu Pharmaceutical.
The ertapenem for injection market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Ertapenem for Injection Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Ertapenem for Injection Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Ertapenem for Injection Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Ertapenem for Injection Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Ertapenem for Injection Market Size & Forecast, 2020-2028
4.5.1 Ertapenem for Injection Market Size and Y-o-Y Growth
4.5.2 Ertapenem for Injection Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Purity >98%
5.2.2 Purity >99%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Intravenous Injection
6.2.2 Intramuscular Injection
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Ertapenem for Injection Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Ertapenem for Injection Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Purity >98%
9.6.2 Purity >99%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Intravenous Injection
9.10.2 Intramuscular Injection
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Purity >98%
10.6.2 Purity >99%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Intravenous Injection
10.10.2 Intramuscular Injection
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Purity >98%
11.6.2 Purity >99%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Intravenous Injection
11.10.2 Intramuscular Injection
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Purity >98%
12.6.2 Purity >99%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Intravenous Injection
12.10.2 Intramuscular Injection
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Purity >98%
13.6.2 Purity >99%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Intravenous Injection
13.10.2 Intramuscular Injection
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Ertapenem for Injection Market: Competitive Dashboard
14.2 Global Ertapenem for Injection Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Savior Lifetec Corporation
14.3.2 ACS Dobfar
14.3.3 Zhejiang Hisun Pharmaceutical
14.3.4 Sun Pharma
14.3.5 Zhejiang Hisoar
14.3.6 Kaliberr Labs
14.3.7 Qilu Pharmaceutical
